Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAB NASDAQ:CMMB NASDAQ:ENSC NASDAQ:RLYB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$0.33-8.1%$0.40$0.24▼$2.53$20.98M0.9791,629 shs492,189 shsCMMBChemomab Therapeutics$1.03-4.2%$1.20$0.87▼$2.55$20.18M0.52129,046 shs106,220 shsENSCEnsysce Biosciences$2.05-1.9%$2.20$1.62▼$14.67$4.96M0.98843,251 shs435,767 shsRLYBRallybio$0.54+15.1%$0.39$0.22▼$1.30$19.35M-1.178.41 million shs913,345 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla-8.10%-6.99%-17.02%-40.86%-81.77%CMMBChemomab Therapeutics-4.21%-5.96%-10.87%-27.82%-12.39%ENSCEnsysce Biosciences-1.91%-8.48%-9.69%-20.23%-69.63%RLYBRallybio+15.05%+7.28%+65.69%+68.77%-61.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCABBioAtla2.0695 of 5 stars3.31.00.00.02.22.50.6CMMBChemomab Therapeutics2.9335 of 5 stars3.53.00.00.03.31.70.6ENSCEnsysce Biosciences0.5252 of 5 stars0.04.00.00.01.10.00.6RLYBRallybio1.8052 of 5 stars3.02.00.00.00.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCABBioAtla 2.50Moderate Buy$5.001,415.15% UpsideCMMBChemomab Therapeutics 3.00Buy$8.50729.27% UpsideENSCEnsysce Biosciences 0.00N/AN/AN/ARLYBRallybio 2.00Hold$10.001,769.16% UpsideCurrent Analyst Ratings BreakdownLatest ENSC, RLYB, BCAB, and CMMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025CMMBChemomab TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCABBioAtla$11M1.75N/AN/A$0.25 per share1.32CMMBChemomab TherapeuticsN/AN/AN/AN/A$0.72 per shareN/AENSCEnsysce BiosciencesN/AN/AN/AN/A$2.59 per shareN/ARLYBRallybio$848K26.25N/AN/A$1.49 per share0.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCABBioAtla-$69.78M-$1.22N/AN/AN/AN/A-373.47%-116.55%8/6/2025 (Estimated)CMMBChemomab Therapeutics-$13.94M-$0.76N/AN/AN/AN/A-106.70%-82.18%8/20/2025 (Estimated)ENSCEnsysce Biosciences-$7.99M-$6.54N/AN/AN/A-109.49%-192.54%-121.77%8/13/2025 (Estimated)RLYBRallybio-$57.78M-$1.09N/AN/AN/A-5,682.19%-72.31%-64.78%8/14/2025 (Estimated)Latest ENSC, RLYB, BCAB, and CMMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/20/2025Q2 2025CMMBChemomab Therapeutics-$0.20N/AN/AN/AN/AN/A8/14/2025Q2 2025BCABBioAtla-$0.29N/AN/AN/AN/AN/A8/13/2025Q2 2025ENSCEnsysce Biosciences-$1.02N/AN/AN/A$0.67 millionN/A5/15/2025Q1 2025CMMBChemomab Therapeutics-$0.20-$0.14+$0.06-$0.14N/AN/A5/13/2025Q1 2025ENSCEnsysce Biosciences-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 million5/8/2025Q1 2025RLYBRallybio-$0.21-$0.21N/A-$0.21N/A$0.21 million5/6/2025Q1 2025BCABBioAtla-$0.28-$0.29-$0.01-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCABBioAtlaN/AN/AN/AN/AN/ACMMBChemomab TherapeuticsN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCABBioAtlaN/A2.352.35CMMBChemomab TherapeuticsN/A5.335.33ENSCEnsysce BiosciencesN/A2.502.50RLYBRallybioN/A14.6814.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCABBioAtla77.23%CMMBChemomab Therapeutics46.05%ENSCEnsysce Biosciences5.63%RLYBRallybio90.34%Insider OwnershipCompanyInsider OwnershipBCABBioAtla11.50%CMMBChemomab Therapeutics11.91%ENSCEnsysce Biosciences7.90%RLYBRallybio8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCABBioAtla6058.42 million51.70 millionOptionableCMMBChemomab Therapeutics2018.86 million16.61 millionNot OptionableENSCEnsysce Biosciences102.37 million2.18 millionNot OptionableRLYBRallybio4041.61 million37.99 millionNot OptionableENSC, RLYB, BCAB, and CMMB HeadlinesRecent News About These CompaniesEvercore ISI Remains a Hold on Rallybio (RLYB)July 16, 2025 | theglobeandmail.comRXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia ... - NasdaqJuly 11, 2025 | nasdaq.comRallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - MorningstarJuly 9, 2025 | morningstar.comMHere's Why Shares in Recursion Pharmaceuticals Surged TodayJuly 8, 2025 | finance.yahoo.comRallybio Sells Interest in REV102 Program to Recursion PharmaceuticalsJuly 8, 2025 | finance.yahoo.comRecursion to buy Rallybio’s ownership in jointly developed bone disorder drugJuly 8, 2025 | msn.comRallybio Sells REV102 Program to Recursion PharmaceuticalsJuly 8, 2025 | tipranks.comRallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic StudyJune 13, 2025 | finance.yahoo.comRallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlookMay 24, 2025 | investing.comRallybio shareholders elect directors, ratify auditorMay 18, 2025 | uk.investing.comRallybio Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finance.yahoo.comRallybio to Present at the 2025 Citizens JMP Life Sciences ConferenceApril 29, 2025 | finance.yahoo.comJones Trading Downgrades Rallybio (RLYB)April 15, 2025 | msn.comRallybio downgraded to Hold from Buy at JonesResearchApril 14, 2025 | markets.businessinsider.comRallybio downgraded to In Line from Outperform at Evercore ISIApril 11, 2025 | markets.businessinsider.comRallybio (RLYB) was downgraded to a Hold Rating at H.C. WainwrightApril 10, 2025 | markets.businessinsider.comRallybio Stock Short Interest Report | NASDAQ:RLYB | BenzingaApril 9, 2025 | benzinga.comRallybio discontinues RLYB212 programApril 9, 2025 | markets.businessinsider.comRallybio sinks as it drops RLYB212 for prevention of FNAITApril 9, 2025 | thepharmaletter.comTHC Wainwright & Co. Downgrades Rallybio (RLYB)April 9, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENSC, RLYB, BCAB, and CMMB Company DescriptionsBioAtla NASDAQ:BCAB$0.33 -0.03 (-8.10%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.34 +0.01 (+2.73%) As of 08/1/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Chemomab Therapeutics NASDAQ:CMMB$1.02 -0.05 (-4.21%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$1.03 +0.01 (+0.98%) As of 08/1/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Ensysce Biosciences NASDAQ:ENSC$2.05 -0.04 (-1.91%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.04 0.00 (-0.24%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.Rallybio NASDAQ:RLYB$0.54 +0.07 (+15.05%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.53 -0.01 (-1.31%) As of 08/1/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
